Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
From January 1, 2024, the EC Decision Reliance Procedure (ECDRP) has been replaced by the new international recognition procedure (IRP) that allows fast approval of products that have already received authorization for the same product from one of the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA)’s specified Reference Regulators (RRs):Australia, Canada, Switzerland, Singapore, Japan, United States, and European Union. The first product approved is Xgeva/Prolia (denosumab), which has also received biosimilar approvals in the US.
To qualify for IRP submission, the product must have the same qualitative and quantitative composition (active substance(s) and excipients) and the same pharmaceutical form from applicants belonging to the same company or group of companies or ‘licensees.’
IRP can be used for chemical and biological active substances, generic applications, hybrid applications, biosimilar applications, and new fixed combination product applications. IRPs can also be used for post-authorization procedures, including line extensions, variations, and renewals.
There are 2 recognition timetables for initial marketing authorization applications:
The MHRA has always been highly supportive of the entry of biosimilars, but its actions came into place after the United Kingdom got out of the European Union. The MHRA was the first regulatory agency to remove clinical efficacy testing of biosimilars with the following statement:
“Although each biosimilar development needs to be evaluated on a case-by-case basis, it is considered that, in most cases, a comparative efficacy trial may not be necessary if sound scientific rationale supports this approach. Therefore, a well-argued justification for the absence of an efficacy trial should be appended to CTD Module 1 of the submitted application”.
Now, it is possible for biosimilars approved in the qualified regions to be automatically available in the United Kingdom or any other country that may decide to follow these guidelines. This action also removes many misconceptions about biosimilars, such as the need to bridge studies when the reference product is not specific to the country of origin or even conducting comparative efficacy testing. This is an opportunity for all countries listed in the IRP list to adopt the same system of qualifying the registration of biosimilars. Moreover, it is an opportunity for all developing countries to adopt this policy, as I suggested in forming a Global Regulatory Agency that is now under consideration by the United Nations.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.